Search

Your search keyword '"Jameson, Catherine"' showing total 3 results
Start Over Author "Jameson, Catherine" Topic systematic review
3 results on '"Jameson, Catherine"'

2. Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data

Author

Whiting, Penny, Birnie, Kate, Sterne, Jonathan, Jameson, Catherine, Skinner, Rod, Phillips, Bob, Barnfield, Mark, Blufpand, Hester, Bokenkamp, Arend, Grönroos, Marika, Lankisch, Petra, and Philips, Bob

Subjects
Male, medicine.medical_specialty, Adolescent, Urology, Renal function, urologic and male genital diseases, Malignancy, Logistic regression, Diagnostic accuracy, Nephrotoxicity, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Neoplasms, Humans, Chemotherapy, Medicine, Renal Insufficiency, 030212 general & internal medicine, Cystatin C, Child, Children, Qualitative Research, reproductive and urinary physiology, Creatinine, biology, business.industry, Cancer, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, Oncology, chemistry, 030220 oncology & carcinogenesis, Systematic review, biology.protein, Female, Cystatin, business
Abstract

We conducted a systematic review and individual patient data (IPD) meta-analysis to examine the utility of cystatin C for evaluation of glomerular function in children with cancer. Eligible studies evaluated the accuracy of cystatin C for detecting poor renal function in children undergoing chemotherapy. Study quality was assessed using QUADAS-2. Authors of four studies shared IPD. We calculated the correlation between log cystatin C and GFR stratified by study and measure of cystatin C. We dichotomized the reference standard at GFR 80 ml/min/1.73m2 and stratified cystatin C at 1 mg/l, to calculate sensitivity and specificity in each study and according to age group (0–4, 5–12, and ≥ 13 years). In sensitivity analyses, we investigated different GFR and cystatin C cut points. We used logistic regression to estimate the association of impaired renal function with log cystatin C and quantified diagnostic accuracy using the area under the ROC curve (AUC). Six studies, which used different test and reference standard thresholds, suggested that cystatin C has the potential to monitor renal function in children undergoing chemotherapy for malignancy. IPD data (504 samples, 209 children) showed that cystatin C has poor sensitivity (63%) and moderate specificity (89%), although use of a GFR cut point of

Published
2017

3. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review.

Author

Whiting, Penny F., Moore, Theresa H.M., Jameson, Catherine M., Davies, Philippa, Rowlands, Mari‐Anne, Burke, Margaret, Beynon, Rebecca, Savovic, Jelena, and Donovan, Jenny L.

Subjects
PROSTATE cancer, CONDUCT of life, LIFE skills, ALTRUISM, BENEVOLENCE
Abstract

To conduct a systematic review of the risks of short-term outcomes after major treatments for clinically localised prostate cancer. MEDLINE, EMBASE and the Cochrane Library were searched from 2004 to January 2013. Study arms that included ≥100 men with localised prostate cancer in receipt of surgery, radiotherapy or active surveillance and reported symptomatic and quality-of-life (QoL) data from 6 to 60 months after treatment were eligible. Data were extracted by one reviewer and checked by another. In all, 64 studies (80 treatment cohorts) were included. Most were single treatment cohorts from the USA or Europe. Radiotherapy was the most common treatment (40 cohorts, including 31 brachytherapy cohorts) followed by prostatectomy (39 cohorts), with only one active surveillance cohort. Most frequently measured symptoms were urinary, followed by sexual, and bowel; QoL was assessed in only 17 cohorts. Most studies used validated measures, although poor data reporting and differences between studies meant that it was not possible to pool data. Data on the precise impact of short-term symptomatic and QoL outcomes after treatment for localised prostate cancer are of insufficient quality for clear guidance to men about the risks to these aspects of their lives. It is important that future studies focus on collecting core outcomes through validated measures and comply with reporting guidelines, so that clear and accurate information can be derived for men considering screening or treatment for prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results